<DOC>
	<DOCNO>NCT00180622</DOCNO>
	<brief_summary>The primary aim study exploit difference COPD patient , chronic smoker without COPD healthy non-smoking subject . This help assess utility inflammatory oxidative marker exhale air sputum compare lung function , clinical parameter computerise tomography ( CT ) .</brief_summary>
	<brief_title>Markers COPD</brief_title>
	<detailed_description />
	<mesh_term>Carbon Monoxide</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>Healthy nonsmoker FEV1 &gt; 80 % predict FEV1 reversibility &lt; 10 % inhale ( beta2agonists Current smoker FEV1 le 80 % predict FEV1 reversibility &lt; 10 % inhale ( beta2agonists Smoking history &gt; 10 packyears Moderate COPD FEV1 4059 % predict FEV1 reversibility &lt; 10 % inhale ( beta2agonists Smoking history &gt; 10 packyears** Severe COPD FEV1 &lt; 40 % predict FEV1 reversibility &lt; 10 % inhale ( beta2agonists Smoking history &gt; 10 packyears FEV1 increase 200 ml 15 % baseline value inhale ( beta2agonists Asthma unstable disease ( FEV1 &lt; 35 % predict ) and/or current , within last 4 week , respiratory tract infection .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>